Attention Deficit Hyperactivity Disorder - Strattera to Add Novel Dimension to the Market

Introduction

Currently, the ADHD market is dominated by methylphenidate (Ritalin and Concerta) and amphetamine (Adderall) based stimulants. However, in November 2002, Eli Lilly’s Strattera (atomoxetine) received FDA approval. Strattera will be the first drug indicated for ADHD that is not a Schedule II Controlled Substance, and this provides Strattera with a plethora of competitive advantages that will see the drug rival Concerta and Adderall. 

Scope

Key data and detailed analysis of the 7 leading pharmaceutical markets: the US, Japan, Germany, France, Italy, Spain, and the UK 

Focus on Eli Lilly’s Strattera, including clinical data assessment and market positioning strategy 

Forecast revenues of the branded market and specific products to 2010 

In-depth analysis of, and strategies to increase, awareness of ADHD in the seven major markets 

Report Highlights

There is a low diagnosis rate of females with ADHD compared to males due to the former having more internalized symptoms. However, Datamonitor has found that females are also less likely to be treated with pharmacotherapy and Datamonitor believes that this is due to clinical trial data focusing on hyperactivity rather than inattentive symptoms. 

Eli Lilly’s Strattera will receive a fast uptake because it the first non-Schedule II drug approved for ADHD. This means that samples can be provided to physicians, prescriptions can be re-filed, and the drug does not have be securely stored. 

Reasons to Purchase

Understand the unmet needs of the ADHD market to optimize growth strategies 

Enhance your understanding of how Eli Lilly’s Strattera will impact the market, and in which areas 

Understand the key mechanisms to drive awareness and diagnosis rates of ADHD, and countries where this is most required 

Increase your competitive intelligence through assessments of product performance to 2010 

Publisher: Datamonitor CNS Central Nervous System Reports 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_CNS.html#a119